Grifols SA
GRFSGrifols, S.A. (Catalan: ) is a global healthcare company and leading producer of plasma-derived medicines founded in Barcelona, Catalonia, Spain, in 1909. With a workforce of over 23,800 employees, Grifols serves more than 110 countries and regions and maintains a direct presence in over 30.
Drugs in Pipeline
44
Phase 3 Programs
23
Upcoming Catalysts
2
Next Catalyst
This month
Market Overview
Stock performance and key metrics
2 upcoming, 1 past
GRF312 5% Phase 2 Est. Readout
Primary completion for GRF312 5% trial (NCT07264517) in Dry Eye Disease
Source1 more catalyst beyond 14 days
Start a 7-day free trial to see all upcoming catalysts
Xembify
Hypogammaglobulinemia
Liquid Alpha₁-PI
Alpha₁-Antitrypsin Deficiency
Alpha-1 MP
Alpha 1-Antitrypsin Deficiency
Albutein 20%
Decompensated Cirrhosis and Ascites
alpha-1 proteinase inhibitor (human)
Alpha 1-Antitrypsin Deficiency
Fibrin Sealant (FS) Grifols
Soft Tissue Surgical Bleeding
IVIG-PEG
Primary Immunodeficiency
Fibrin Sealant Grifols
Excessive Bleeding During Surgery
Specific intravenous anti-hepatitis B immunoglobulin
Hepatitis B, Chronic
IGIV3I Grifols
Immune (Idiopathic) Thrombocytopenic Purpura
GAMUNEX-C
COVID-19
Alpha-1 15%
Alpha1-Antitrypsin Deficiency
Immune Globulin IV (Human), 10% Caprylate/Chromatography Purified
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
Albumin 5%
Alzheimer's Disease
IGIV3I Grifols 10%
Idiopathic Thrombocytopenic Purpura
FS Grifols
Target Bleeding Site During Peripheral Vascular Surgery
Hepatitis B immune globulin
Hepatitis B
Immune Globulin Intravenous [Human], 10% Caprylate/Chromatography Purified
Immunologic Deficiency Syndrome
IGSC 20%
Primary Immunodeficiency
Plasma-derived AT-III concentrate
Antithrombin III Deficiency
IGIV-C 10%
Primary Immunodeficiency
IGIV-C
Myasthenia Gravis, Generalized
Gamunex-C, 10% Injectable Solution
Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma
Immune Globulin Intravenous (Human)
Immunologic Deficiency Syndrome
Convalescent anti-SARS-CoV-2 MBT Plasma
COVID-19
Prolastin-C, 60 mg/kg
Emphysema
GRF312 5%
Dry Eye Disease
Prolastin
COVID-19
Human thrombin
Hemostasis
Alpha1-Proteinase Inhibitor (Human)
Cystic Fibrosis
Antithrombin III
Acquired Antithrombin III Deficiency
BeneFIX
Hemophilia B
Albumin (Human) 20%, United States Pharmacopeia (USP)
Alpha 1-Antitrypsin Deficiency
Plasmin
Acute Peripheral Arterial Occlusion
Alpha-1 HC 100 mg
Cystic Fibrosis
Albutein 5%
Alzheimer's Disease
Intravenous Immune Globulin
COVID-19
Albumin
Amyotrophic Lateral Sclerosis
Immune Globulin IV [Human], 10% Caprylate/Chromatography Purified
Purpura, Thrombocytopenic, Idiopathic
Albumin (Human) 25%, United States Pharmacopeia (USP)
Multiple Sclerosis, Relapsing-Remitting
Plasmin (Human)
Acute Ischemic Stroke
Human Plasma-Derived Fibrinogen Concentrate
Congenital Afibrinogenemia
intramuscular hepatitis B virus immune globulin
Hepatitis B, Chronic
AT-III (Human)
Cardiac Surgery
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Xembify | Phase 3 | Hypogammaglobulinemia | - | - |
Liquid Alpha₁-PI | Phase 3 | Alpha₁-Antitrypsin Deficiency | - | - |
Alpha-1 MP | Phase 3 | Alpha 1-Antitrypsin Deficiency | - | - |
Albutein 20% | Phase 3 | Decompensated Cirrhosis and Ascites | - | - |
alpha-1 proteinase inhibitor (human) | Phase 3 | Alpha 1-Antitrypsin Deficiency | - | - |
Fibrin Sealant (FS) Grifols | Phase 3 | Soft Tissue Surgical Bleeding | - | - |
IVIG-PEG | Phase 3 | Primary Immunodeficiency | - | - |
Fibrin Sealant Grifols | Phase 3 | Excessive Bleeding During Surgery | - | - |
Specific intravenous anti-hepatitis B immunoglobulin | Phase 3 | Hepatitis B, Chronic | - | - |
IGIV3I Grifols | Phase 3 | Immune (Idiopathic) Thrombocytopenic Purpura | - | - |
GAMUNEX-C | Phase 3 | COVID-19 | - | - |
Alpha-1 15% | Phase 3 | Alpha1-Antitrypsin Deficiency | - | - |
Immune Globulin IV (Human), 10% Caprylate/Chromatography Purified | Phase 3 | Polyradiculoneuropathy, Chronic Inflammatory Demyelinating | - | - |
Albumin 5% | Phase 3 | Alzheimer's Disease | - | - |
IGIV3I Grifols 10% | Phase 3 | Idiopathic Thrombocytopenic Purpura | - | - |
FS Grifols | Phase 3 | Target Bleeding Site During Peripheral Vascular Surgery | - | - |
Hepatitis B immune globulin | Phase 3 | Hepatitis B | - | - |
Immune Globulin Intravenous [Human], 10% Caprylate/Chromatography Purified | Phase 3 | Immunologic Deficiency Syndrome | - | - |
IGSC 20% | Phase 3 | Primary Immunodeficiency | - | - |
Plasma-derived AT-III concentrate | Phase 3 | Antithrombin III Deficiency | - | - |
IGIV-C 10% | Phase 3 | Primary Immunodeficiency | - | - |
IGIV-C | Phase 3 | Myasthenia Gravis, Generalized | - | - |
Gamunex-C, 10% Injectable Solution | Phase 3 | Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma | - | - |
Immune Globulin Intravenous (Human) | Phase 2 | Immunologic Deficiency Syndrome | - | - |
Convalescent anti-SARS-CoV-2 MBT Plasma | Phase 2 | COVID-19 | - | - |
Prolastin-C, 60 mg/kg | Phase 2 | Emphysema | - | - |
GRF312 5% | Phase 2 | Dry Eye Disease | - | - |
Prolastin | Phase 2 | COVID-19 | - | - |
Human thrombin | Phase 2 | Hemostasis | - | - |
Alpha1-Proteinase Inhibitor (Human) | Phase 2 | Cystic Fibrosis | - | - |
Antithrombin III | Phase 2 | Acquired Antithrombin III Deficiency | - | - |
BeneFIX | Phase 2 | Hemophilia B | - | - |
Albumin (Human) 20%, United States Pharmacopeia (USP) | Phase 2 | Alpha 1-Antitrypsin Deficiency | - | - |
Plasmin | Phase 2 | Acute Peripheral Arterial Occlusion | - | - |
Alpha-1 HC 100 mg | Phase 2 | Cystic Fibrosis | - | - |
Albutein 5% | Phase 2 | Alzheimer's Disease | - | - |
Intravenous Immune Globulin | Phase 2 | COVID-19 | - | - |
Albumin | Phase 2 | Amyotrophic Lateral Sclerosis | - | - |
Immune Globulin IV [Human], 10% Caprylate/Chromatography Purified | Phase 2 | Purpura, Thrombocytopenic, Idiopathic | - | - |
Albumin (Human) 25%, United States Pharmacopeia (USP) | Phase 2 | Multiple Sclerosis, Relapsing-Remitting | - | - |
Plasmin (Human) | Phase 2 | Acute Ischemic Stroke | - | - |
Human Plasma-Derived Fibrinogen Concentrate | Phase 2 | Congenital Afibrinogenemia | - | - |
intramuscular hepatitis B virus immune globulin | Phase 2 | Hepatitis B, Chronic | - | - |
AT-III (Human) | Phase 2 | Cardiac Surgery | - | - |